Enlivex Therapeutics Stock Shares Owned By Insiders

ENLV Stock

USD 1.07 0.14 15.05%

Enlivex Therapeutics fundamentals help investors to digest information that contributes to Enlivex Therapeutics' financial success or failures. It also enables traders to predict the movement of Enlivex Stock. The fundamental analysis module provides a way to measure Enlivex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enlivex Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Enlivex Therapeutics Company Shares Owned By Insiders Analysis

Enlivex Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Enlivex Therapeutics Shares Owned By Insiders

5.73 %

Most of Enlivex Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enlivex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Enlivex Shares Owned By Insiders Driver Correlations

Understanding the fundamental principles of building solid financial models for Enlivex Therapeutics is extremely important. It helps to project a fair market value of Enlivex Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Enlivex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enlivex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enlivex Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Treasury Stock	Long Term Debt	Good Will	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Capital Surpluse	Net Tangible Assets	Net Invested Capital	Net Working Capital	Capital Stock	Short Term Debt
Total Assets		1.0	0.73	0.46	0.81	0.6	0.47	0.37	0.03	0.56	0.57	-0.32	-0.23	0.12	0.62	-0.19	0.59	0.64	0.63	0.53	0.6
Total Stockholder Equity	1.0		0.75	0.47	0.77	0.63	0.41	0.33	0.01	0.6	0.6	-0.29	-0.18	0.08	0.58	-0.17	0.54	0.6	0.6	0.48	0.56
Accounts Payable	0.73	0.75		-0.01	0.46	0.7	0.05	0.32	0.01	0.65	0.69	-0.28	-0.05	-0.09	0.19	-0.02	0.06	0.1	0.07	0.11	0.21
Short Term Investments	0.46	0.47	-0.01		0.34	-0.03	0.35	-0.05	0.08	-0.04	-0.07	0.17	-0.02	0.12	0.64	-0.16	0.58	0.6	0.66	0.43	0.4
Total Liab	0.81	0.77	0.46	0.34		0.16	0.82	0.62	0.25	0.1	0.17	-0.51	-0.6	0.43	0.79	-0.31	0.82	0.83	0.81	0.83	0.83
Intangible Assets	0.6	0.63	0.7	-0.03	0.16		-0.22	0.06	-0.1	0.97	0.95	0.18	0.27	-0.22	-0.26	0.03	-0.19	-0.18	-0.18	-0.2	-0.16
Common Stock	0.47	0.41	0.05	0.35	0.82	-0.22		0.76	0.55	-0.35	-0.13	-0.32	-0.83	0.33	0.76	-0.5	0.89	0.86	0.84	0.97	0.84
Property Plant Equipment	0.37	0.33	0.32	-0.05	0.62	0.06	0.76		0.77	-0.14	0.17	-0.24	-0.87	-0.14	0.35	-0.43	0.6	0.49	0.45	0.77	0.67
Treasury Stock	0.03	0.01	0.01	0.08	0.25	-0.1	0.55	0.77		-0.31	-0.05	0.26	-0.76	-0.19	0.15	-0.38	0.46	0.2	0.2	0.56	0.29
Long Term Debt	0.56	0.6	0.65	-0.04	0.1	0.97	-0.35	-0.14	-0.31		0.88	0.1	0.44	-0.16	-0.28	0.13	-0.27	-0.23	-0.22	-0.31	-0.24
Good Will	0.57	0.6	0.69	-0.07	0.17	0.95	-0.13	0.17	-0.05	0.88		0.21	0.16	-0.24	-0.24	-0.03	-0.19	-0.13	-0.13	-0.14	-0.09
Net Debt	-0.32	-0.29	-0.28	0.17	-0.51	0.18	-0.32	-0.24	0.26	0.1	0.21		0.24	-0.15	-0.49	0.06	-0.36	-0.46	-0.39	-0.38	-0.6
Retained Earnings	-0.23	-0.18	-0.05	-0.02	-0.6	0.27	-0.83	-0.87	-0.76	0.44	0.16	0.24		-0.07	-0.52	0.23	-0.72	-0.6	-0.58	-0.83	-0.71
Net Receivables	0.12	0.08	-0.09	0.12	0.43	-0.22	0.33	-0.14	-0.19	-0.16	-0.24	-0.15	-0.07		0.37	-0.02	0.21	0.28	0.29	0.2	0.12
Total Current Assets	0.62	0.58	0.19	0.64	0.79	-0.26	0.76	0.35	0.15	-0.28	-0.24	-0.49	-0.52	0.37		-0.26	0.88	0.93	0.93	0.81	0.84
Capital Surpluse	-0.19	-0.17	-0.02	-0.16	-0.31	0.03	-0.5	-0.43	-0.38	0.13	-0.03	0.06	0.23	-0.02	-0.26		-0.35	-0.33	-0.33	-0.4	-0.3
Net Tangible Assets	0.59	0.54	0.06	0.58	0.82	-0.19	0.89	0.6	0.46	-0.27	-0.19	-0.36	-0.72	0.21	0.88	-0.35		0.94	0.94	0.96	0.89
Net Invested Capital	0.64	0.6	0.1	0.6	0.83	-0.18	0.86	0.49	0.2	-0.23	-0.13	-0.46	-0.6	0.28	0.93	-0.33	0.94		1.0	0.9	0.93
Net Working Capital	0.63	0.6	0.07	0.66	0.81	-0.18	0.84	0.45	0.2	-0.22	-0.13	-0.39	-0.58	0.29	0.93	-0.33	0.94	1.0		0.88	0.91
Capital Stock	0.53	0.48	0.11	0.43	0.83	-0.2	0.97	0.77	0.56	-0.31	-0.14	-0.38	-0.83	0.2	0.81	-0.4	0.96	0.9	0.88		0.91
Short Term Debt	0.6	0.56	0.21	0.4	0.83	-0.16	0.84	0.67	0.29	-0.24	-0.09	-0.6	-0.71	0.12	0.84	-0.3	0.89	0.93	0.91	0.91

Click cells to compare fundamentals

Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Competition

Predict Enlivex Therapeutics

Based on the latest financial disclosure, 5.73% of Enlivex Therapeutics are shares owned by insiders. This is 62.25% lower than that of the Software sector and 59.59% lower than that of the Information Technology industry. The shares owned by insiders for all United States stocks is 43.21% higher than that of the company.

Enlivex Shares Owned By Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.

Enlivex Therapeutics is currently under evaluation in shares owned by insiders category among its peers.

Enlivex Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Enlivex Therapeutics from analyzing Enlivex Therapeutics' financial statements. These drivers represent accounts that assess Enlivex Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Enlivex Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	72.6M	111.0M	111.6M	72.5M	50.2M	50.2M
Enterprise Value	68.7M	105.5M	101.0M	29.5M	50.3M	41.9M

Enlivex Fundamentals

	Return On Equity	-0.61
	Return On Asset	-0.27
	Current Valuation	(5.21 M)
	Shares Outstanding	21.41 M
	Shares Owned By Insiders	5.73 %
	Shares Owned By Institutions	18.80 %
	Number Of Shares Shorted	160.14 K
	Price To Earning	(11.97) X
	Price To Book	0.70 X
	EBITDA	(28.22 M)
	Net Income	(29.07 M)
	Cash And Equivalents	62.48 M
	Cash Per Share	3.40 X
	Total Debt	1.03 M
	Debt To Equity	0.08 %
	Current Ratio	15.44 X
	Book Value Per Share	1.37 X
	Cash Flow From Operations	(23.52 M)
	Short Ratio	1.23 X
	Earnings Per Share	(1.18) X
	Target Price	9.5
	Beta	1.11
	Market Capitalization	19.89 M
	Total Asset	36.83 M
	Retained Earnings	(112.09 M)
	Working Capital	27.7 M
	Current Asset	6 M
	Current Liabilities	671.32 K
	Net Asset	36.83 M

About Enlivex Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC